This study is being done to determine if parenterally administered ascorbic acid (Vitamin C)
given at the time of lung transplant is safe. Vitamin C may be an effective intervention
towards primary graft dysfunction (PGD). The study will enroll 69 participants who consent to
the intervention. Participants who do not consent to the intervention will be treated
according to standard-of-care, but may choose to be consented to have their data
retrospectively reviewed. Based on our consent rate, this group may include 40-70
participants. Participants will be on study for up to 12 months.